In conclusion, we have found a novel surface marker in human osteosarcoma, ALCAM, which we have used to specifically target osteosarcoma cells with a novel engineered drug-loaded hybrid PLN formulation anti-ALCAM immunoconjugate. The gene discussed is ALCAM; the disease is osteosarcoma.